[HLIND] YoY Annualized Quarter Result on 31-Dec-2017 [#2]

Stock
[HLIND] HONG LEONG INDUSTRIES BHD
Announcement Date
05-Feb-2018
Admission Sponsor
-
Sponsor
-
Financial Year
30-Jun-2018
Quarter
31-Dec-2017 [#2]
Profit Trend
QoQ- 0.66%
YoY- 23.51%
Quarter Report
Latest QR
Upcoming QR
HLIND's Result
HLIND's Financial Summary
View:
Show?
Annualized Quarter Result
31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 CAGR
Revenue 2,846,678 3,048,256 2,751,522 2,523,474 2,254,558 2,123,996 2,120,090 5.02%
PBT 498,974 472,564 470,196 470,098 364,840 326,154 324,382 7.43%
Tax -95,338 -97,728 -81,698 -72,052 -52,118 -51,302 -108,426 -2.11%
NP 403,636 374,836 388,498 398,046 312,722 274,852 215,956 10.97%
-
NP to SH 301,922 282,902 313,570 329,608 266,866 238,150 167,578 10.29%
-
Tax Rate 19.11% 20.68% 17.38% 15.33% 14.29% 15.73% 33.43% -
Total Cost 2,443,042 2,673,420 2,363,024 2,125,428 1,941,836 1,849,144 1,904,134 4.23%
-
Net Worth 1,800,566 1,720,681 1,566,550 1,374,095 1,401,257 1,279,878 1,141,035 7.89%
Dividend
31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 CAGR
Div 106,839 106,757 94,181 92,844 92,594 80,185 74,013 6.30%
Div Payout % 35.39% 37.74% 30.04% 28.17% 34.70% 33.67% 44.17% -
Equity
31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 CAGR
Net Worth 1,800,566 1,720,681 1,566,550 1,374,095 1,401,257 1,279,878 1,141,035 7.89%
NOSH 327,903 327,903 327,903 327,905 327,905 308,404 308,387 1.02%
Ratio Analysis
31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 CAGR
NP Margin 14.18% 12.30% 14.12% 15.77% 13.87% 12.94% 10.19% -
ROE 16.77% 16.44% 20.02% 23.99% 19.04% 18.61% 14.69% -
Per Share
31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 CAGR
RPS 905.91 970.80 876.45 815.39 730.46 688.70 687.48 4.70%
EPS 96.08 90.10 99.92 106.42 86.52 77.22 54.34 9.95%
DPS 34.00 34.00 30.00 30.00 30.00 26.00 24.00 5.97%
NAPS 5.73 5.48 4.99 4.44 4.54 4.15 3.70 7.55%
Adjusted Per Share Value based on latest NOSH - 327,905
31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 CAGR
RPS 868.15 929.62 839.13 769.58 687.57 647.75 646.56 5.02%
EPS 92.08 86.28 95.63 100.52 81.39 72.63 51.11 10.29%
DPS 32.58 32.56 28.72 28.31 28.24 24.45 22.57 6.30%
NAPS 5.4912 5.2475 4.7775 4.1906 4.2734 3.9032 3.4798 7.89%
Price Multiplier on Financial Quarter End Date
31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 CAGR
Date 31/12/20 31/12/19 31/12/18 29/12/17 30/12/16 31/12/15 31/12/14 -
Price 8.89 10.42 8.50 9.69 9.40 5.93 4.49 -
P/RPS 0.98 1.07 0.97 1.19 1.29 0.86 0.65 7.07%
P/EPS 9.25 11.57 8.51 9.10 10.87 7.68 8.26 1.90%
EY 10.81 8.65 11.75 10.99 9.20 13.02 12.10 -1.85%
DY 3.82 3.26 3.53 3.10 3.19 4.38 5.35 -5.45%
P/NAPS 1.55 1.90 1.70 2.18 2.07 1.43 1.21 4.20%
Price Multiplier on Announcement Date
31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 CAGR
Date 26/02/21 26/02/20 18/02/19 05/02/18 06/02/17 02/02/16 22/01/15 -
Price 8.18 9.40 9.42 9.50 9.76 5.62 4.35 -
P/RPS 0.90 0.97 1.07 1.17 1.34 0.82 0.63 6.11%
P/EPS 8.51 10.43 9.43 8.92 11.29 7.28 8.01 1.01%
EY 11.75 9.58 10.60 11.21 8.86 13.74 12.49 -1.01%
DY 4.16 3.62 3.18 3.16 3.07 4.63 5.52 -4.60%
P/NAPS 1.43 1.72 1.89 2.14 2.15 1.35 1.18 3.25%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment